<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35080077</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-9568</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The European journal of neuroscience</Title><ISOAbbreviation>Eur J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1356</StartPage><EndPage>1372</EndPage><MedlinePgn>1356-1372</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ejn.15608</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a lethal and incurable neurodegenerative disease due to the loss of upper and lower motor neurons, which leads to muscle weakness, atrophy, and paralysis. Sigma-1 receptor (&#x3c3;-1R) is a ligand-operated protein that exhibits pro-survival and anti-apoptotic properties. In addition, mutations in its codifying gene are linked to development of juvenile ALS pointing to an important role in ALS. Here, we investigated the disease-modifying effects of pridopidine, a &#x3c3;-1R agonist, using a delayed onset SOD1 G93A mouse model of ALS. Mice were administered a continuous release of pridopidine (3.0&#x2009;mg/kg/day) for 4 weeks starting before the appearance of any sign of muscle weakness. Mice were monitored weekly and several behavioural tests were used to evaluate muscle strength, motor coordination and gait patterns. Pridopidine-treated SOD1 G93A mice showed genotype-specific effects with the prevention of cachexia. In addition, these effects exhibited significant improvement of motor behaviour 5 weeks after treatment ended. However, the survival of the animals was not extended. In summary, these results show that pridopidine can modify the disease phenotype of ALS-associated cachexia and motor deficits in a SOD1 G93A mouse model.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Est&#xe9;vez-Silva</LastName><ForeName>H&#xe9;ctor M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0002-3706-1320</Identifier><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ciencias M&#xe9;dicas B&#xe1;sicas, Instituto de Tecnolog&#xed;as Biom&#xe9;dicas (ITB), Universidad de La Laguna, Santa Cruz de Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mediavilla</LastName><ForeName>Tom&#xe1;s</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5589-9864</Identifier><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacobbo</LastName><ForeName>Bruno Lima</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-2507-7675</Identifier><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xijia</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-8143-8500</Identifier><AffiliationInfo><Affiliation>Ume&#xe5; School of Business, Economics and Statistics, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultan</LastName><ForeName>Fahad R</ForeName><Initials>FR</Initials><Identifier Source="ORCID">0000-0001-9194-9905</Identifier><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcellino</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-4618-7267</Identifier><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Neurosci</MedlineTA><NlmUniqueID>8918110</NlmUniqueID><ISSNLinking>0953-816X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>HD4TW8S2VK</RegistryNumber><NameOfSubstance UI="C483720">pridopidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002100" MajorTopicYN="N">Cachexia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SOD1G93A</Keyword><Keyword MajorTopicYN="N">motor function</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword><Keyword MajorTopicYN="N">preclinical research</Keyword><Keyword MajorTopicYN="N">pridopidine</Keyword><Keyword MajorTopicYN="N">sigma-1 receptor</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35080077</ArticleId><ArticleId IdType="pmc">PMC9305776</ArticleId><ArticleId IdType="doi">10.1111/ejn.15608</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acevedo&#x2010;Arozena, A. , Kalmar, B. , Essa, S. , Ricketts, T. , Joyce, P. , Kent, R. , Rowe, C. , Parker, A. , Gray, A. , Hafezparast, M. , Thorpe, J. R. , Greensmith, L. , &amp; Fisher, E. M. C. (2011). A comprehensive assessment of the SOD1G93A low&#x2010;copy transgenic mouse, which models human amyotrophic lateral sclerosis. Disease Models &amp; Mechanisms, 4(5), 686&#x2013;700. 10.1242/dmm.007237</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.007237</ArticleId><ArticleId IdType="pmc">PMC3180233</ArticleId><ArticleId IdType="pubmed">21540242</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander, G. M. , Erwin, K. L. , Byers, N. , Deitch, J. S. , Augelli, B. J. , Blankenhorn, E. P. , &amp; Heiman&#x2010;Patterson, T. D. (2004). Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Research. Molecular Brain Research, 130(1&#x2013;2), 7&#x2013;15. 10.1016/j.molbrainres.2004.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molbrainres.2004.07.002</ArticleId><ArticleId IdType="pubmed">15519671</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Saif, A. , Al&#x2010;Mohanna, F. , &amp; Bohlega, S. (2011). A mutation in sigma&#x2010;1 receptor causes juvenile amyotrophic lateral sclerosis. Annals of Neurology, 70(6), 913&#x2013;919. 10.1002/ana.22534</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22534</ArticleId><ArticleId IdType="pubmed">21842496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ari, C. , Poff, A. , Held, H. , Fiorelli, T. , Goldhagen, C. , &amp; D'Agostino, D. (2014). Increased TCA cycle intermediates in response to diet with Deanna protocol in ALS mouse model (578.3). The FASEB Journal, 28(S1), 578.3. 10.1096/fasebj.28.1_supplement.578.3</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.28.1_supplement.578.3</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates, D. , M&#xe4;chler, M. , Bolker, B. , &amp; Walker, S. (2015). Fitting linear mixed&#x2010;effects models Usinglme4. Journal of Statistical Software, 67(1), 1&#x2013;48. 10.18637/jss.v067.i01</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v067.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Birve, A. , Neuwirth, C. , Weber, M. , Marklund, S. L. , Nilsson, A. C. , Jonsson, P. A. , &amp; Andersen, P. M. (2010). A novel SOD1 splice site mutation associated with familial ALS revealed by SOD activity analysis. Human Molecular Genetics, 19(21), 4201&#x2013;4206. 10.1093/hmg/ddq338</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq338</ArticleId><ArticleId IdType="pubmed">20709807</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, S. P. , Trueman, R. C. , &amp; Dunnett, S. B. (2012). Assessment of motor coordination and balance in mice using the Rotarod, elevated bridge, and footprint tests. Current Protocols in Mouse Biology, 2(1), 37&#x2013;53. 10.1002/9780470942390.mo110165</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470942390.mo110165</ArticleId><ArticleId IdType="pubmed">26069004</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitanio, D. , Vasso, M. , Ratti, A. , Grignaschi, G. , Volta, M. , Moriggi, M. , Daleno, C. , Bendotti, C. , Silani, V. , &amp; Gelfi, C. (2012). Molecular signatures of amyotrophic lateral sclerosis disease progression in hind and forelimb muscles of an SOD1(G93A) mouse model. Antioxidants &amp; Redox Signaling, 17(10), 1333&#x2013;1350. 10.1089/ars.2012.4524</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4524</ArticleId><ArticleId IdType="pmc">PMC3437050</ArticleId><ArticleId IdType="pubmed">22563797</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter, M. , &amp; Shieh, J. (2015). Chapter 2 &#x2010; Animal Behavior. In Carter M. &amp; Shieh J. (Eds.), Guide to research techniques in neuroscience (second edition) (pp. 39&#x2013;71). Academic Press. 10.1016/B978-0-12-800511-8.00002-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-800511-8.00002-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu, A. Y. , Zhai, P. , Dal Canto, M. C. , Peters, T. M. , Kwon, Y. W. , Prattis, S. M. , &amp; Gurney, M. E. (1995). Age&#x2010;dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Molecular and Cellular Neurosciences, 6(4), 349&#x2013;362. 10.1006/mcne.1995.1027</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.1995.1027</ArticleId><ArticleId IdType="pubmed">8846004</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon, R. M. J. (2013). Measuring the strength of mice. Journal of Visualized Experiments, 76, e2610. 10.3791/2610</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2610</ArticleId><ArticleId IdType="pmc">PMC3725666</ArticleId><ArticleId IdType="pubmed">23770643</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, H. X. , Hentati, A. , Tainer, J. A. , Iqbal, Z. , Cayabyab, A. , Hung, W. Y. , Getzoff, E. D. , Hu, P. , Herzfeldt, B. , Roos, R. P. , Warner, C. , Deng, G. , Soriano, E. , Smyth, C. , Parge, H. E. , Ahmed, A. , Roses, A. D. , Hallewell, R. A. , Pericak&#x2010;Vance, M. A. , &amp; Siddique, T. (1993). Amyotrophic lateral sclerosis and structural defects in cu, Zn Superoxide Dismutase. Science, 261(5124), 1047&#x2013;1051. 10.1126/science.8351519</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8351519</ArticleId><ArticleId IdType="pubmed">8351519</ArticleId></ArticleIdList></Reference><Reference><Citation>Dion, P. A. , Daoud, H. , &amp; Rouleau, G. A. (2009). Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nature Reviews. Genetics, 10(11), 769&#x2013;782. 10.1038/nrg2680</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2680</ArticleId><ArticleId IdType="pubmed">19823194</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge, J. C. , Treleaven, C. M. , Fidler, J. A. , Tamsett, T. J. , Bao, C. , Searles, M. , Taksir, T. V. , Misra, K. , Sidman, R. L. , Cheng, S. H. , &amp; Shihabuddin, L. S. (2013). Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proceedings of the National Academy of Sciences, 110(26), 10812&#x2013;10817. 10.1073/pnas.1308421110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1308421110</ArticleId><ArticleId IdType="pmc">PMC3696768</ArticleId><ArticleId IdType="pubmed">23754387</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen, A. , Kiernan, M. , Mitsumoto, H. , &amp; Swash, M. (2014). Amyotrophic lateral sclerosis: a long preclinical period? Journal of Neurology, Neurosurgery, and Psychiatry, 85(11), 1232&#x2013;1238. 10.1136/jnnp-2013-307135</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-307135</ArticleId><ArticleId IdType="pubmed">24648037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney, M. E. , Pu, H. , Chiu, A. Y. , Dal Canto, M. C. , Polchow, C. Y. , Alexander, D. D. , Caliendo, J. , Hentati, A. , Kwon, Y. W. , Deng, H. X. , Chen, W. , Zhai, P. , Sufit, R. L. , &amp; Siddique, T. (1994). Motor neuron degeneration in mice that express a human cu, Zn Superoxide Dismutase Mutation. Science, 264(5166), 1772&#x2013;1775. 10.1126/science.8209258</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Harandi, V. M. (2016). A muscle perspective on the pathophysiology of amyotrophic lateral sclerosis: Differences between extraocular and limb muscles. PhD dissertation. Ume&#xe5;, Umea University.</Citation></Reference><Reference><Citation>Hardiman, O. , al&#x2010;Chalabi, A. , Chio, A. , Corr, E. M. , Logroscino, G. , Robberecht, W. , Shaw, P. J. , Simmons, Z. , &amp; Van den Berg, L. H. (2017). Amyotrophic lateral sclerosis. Nature Reviews. Disease Primers, 3, 17071. 10.1038/nrdp.2017.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros, T. , Kidd, J. D. , Moreno, A. J. , Thompson, K. , Gill, A. , &amp; Vieira, F. G. (2015). A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1&#x2010;G93A mouse model of ALS. Journal of Visualized Experiments, (104), e53257. 10.3791/53257</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/53257</ArticleId><ArticleId IdType="pmc">PMC4692639</ArticleId><ArticleId IdType="pubmed">26485052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi, T. , &amp; Su, T. P. (2005). The potential role of sigma&#x2010;1 receptors in lipid transport and lipid raft reconstitution in the brain: Implication for drug abuse. Life Sciences, 77(14), 1612&#x2013;1624. 10.1016/j.lfs.2005.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2005.05.009</ArticleId><ArticleId IdType="pubmed">16002098</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi, T. , &amp; Su, T. P. (2007). Sigma&#x2010;1 receptor chaperones at the ER&#x2010;mitochondrion interface regulate ca(2+) signaling and cell survival. Cell, 131(3), 596&#x2013;610. 10.1016/j.cell.2007.08.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.08.036</ArticleId><ArticleId IdType="pubmed">17981125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer, R. , Lanznaster, D. , Vourc'h, P. , Andres, C. , Bakkouche, S. , Beltran, S. , Blasco, H. , Corcia, P. , &amp; Couratier, P. (2020). Advances in disease&#x2010;modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy, 21(9), 1103&#x2013;1110. 10.1080/14656566.2020.1746270</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2020.1746270</ArticleId><ArticleId IdType="pubmed">32242755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu, A. , Gradus, T. , Altman, T. , Maimon, R. , Saraf Avraham, N. , Geva, M. , Hayden, M. , &amp; Perlson, E. (2019a). Targeting the Sigma&#x2010;1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model. Cell Death &amp; Disease, 10(3), 210. 10.1038/s41419-019-1451-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1451-2</ArticleId><ArticleId IdType="pmc">PMC6397200</ArticleId><ArticleId IdType="pubmed">30824685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu, A. , Gradus, T. , Altman, T. , Maimon, R. , Saraf Avraham, N. , Geva, M. , Hayden, M. , &amp; Perlson, E. (2019b). Targeting the Sigma&#x2010;1 receptor via Pridopidine ameliorates central features of ALS pathology in a SOD1G93A model. Cell Death &amp; Disease, 10(3), 210. 10.1038/s41419-019-1451-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1451-2</ArticleId><ArticleId IdType="pmc">PMC6397200</ArticleId><ArticleId IdType="pubmed">30824685</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston, T. H. , Geva, M. , Steiner, L. , Orbach, A. , Papapetropoulos, S. , Savola, J. M. , Reynolds, I. J. , Ravenscroft, P. , Hill, M. , Fox, S. H. , Brotchie, J. M. , Laufer, R. , &amp; Hayden, M. R. (2019). Pridopidine, a clinic&#x2010;ready compound, reduces 3,4&#x2010;dihydroxyphenylalanine&#x2010;induced dyskinesia in parkinsonian macaques. Movement Disorders, 34(5), 708&#x2013;716. 10.1002/mds.27565</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27565</ArticleId><ArticleId IdType="pubmed">30575996</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, F. J. (2017). Introduction to sigma proteins: evolution of the concept of sigma receptors. Handbook of Experimental Pharmacology, 244, 1&#x2013;11. 10.1007/164_2017_41</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/164_2017_41</ArticleId><ArticleId IdType="pubmed">28871306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang, L. , Zetterstr&#xf6;m, P. , Br&#xe4;nnstr&#xf6;m, T. , Marklund, S. L. , Danielsson, J. , &amp; Oliveberg, M. (2015). SOD1 aggregation in ALS mice shows simplistic test tube behavior. Proceedings of the National Academy of Sciences of the United States of America, 112(32), 9878&#x2013;9883. 10.1073/pnas.1503328112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1503328112</ArticleId><ArticleId IdType="pmc">PMC4538623</ArticleId><ArticleId IdType="pubmed">26221023</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, D. P. , Schmidt, C. , Billings, T. , &amp; Davisson, M. T. (2003). Quantitative PCR genotyping assay for the Ts65Dn mouse model of Down syndrome. Biotechniques, 35(6), 1170&#x2013;1180.</Citation><ArticleIdList><ArticleId IdType="pubmed">14682051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso, R. , Oliv&#xe1;n, S. , Rando, A. , Casas, C. , Osta, R. , &amp; Navarro, X. (2012). Sigma&#x2010;1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics, 9(4), 814&#x2013;826. 10.1007/s13311-012-0140-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-012-0140-y</ArticleId><ArticleId IdType="pmc">PMC3480575</ArticleId><ArticleId IdType="pubmed">22935988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann, A. , &amp; Chesselet, M.&#x2010;F. (2015). Chapter 8&#x2014;Techniques for motor assessment in rodents. In LeDoux M. S. (Ed.), Movement Disorders (Second Edition) (pp. 139&#x2013;157). Academic Press. 10.1016/B978-0-12-405195-9.00008-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-405195-9.00008-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez&#x2010;Huenchullan, S. F. , McLennan, S. V. , Ban, L. A. , Morsch, M. , Twigg, S. M. , &amp; Tam, C. S. (2017). Utility and reliability of non&#x2010;invasive muscle function tests in high&#x2010;fat&#x2010;fed mice. Experimental Physiology, 102(7), 773&#x2013;778. 10.1113/EP086328</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/EP086328</ArticleId><ArticleId IdType="pubmed">28497900</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice, T. , Meunier, J. , Feng, B. , Ieni, J. , &amp; Monaghan, D. T. (2006). Interaction with sigma(1) protein, but not N&#x2010;methyl&#x2010;D&#x2010;aspartate receptor, is involved in the pharmacological activity of donepezil. The Journal of Pharmacology and Experimental Therapeutics, 317(2), 606&#x2013;614. 10.1124/jpet.105.097394</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.105.097394</ArticleId><ArticleId IdType="pubmed">16397090</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov, T. A. , Epstein, M. L. , Andersen, K. A. , Ziskind&#x2010;Conhaim, L. , &amp; Ruoho, A. E. (2010). The sigma&#x2010;1 receptor is enriched in postsynaptic sites of C&#x2010;terminals in mouse motoneurons. An Anatomical and Behavioral Study. Neuroscience, 167(2), 247&#x2013;255. 10.1016/j.neuroscience.2010.02.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.02.022</ArticleId><ArticleId IdType="pmc">PMC2862368</ArticleId><ArticleId IdType="pubmed">20167253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov, T. A. , Epstein, M. L. , Verbny, Y. I. , Huerta, M. S. , Zaitoun, I. , Ziskind&#x2010;Conhaim, L. , &amp; Ruoho, A. E. (2013). Lack of sigma&#x2010;1 receptor exacerbates ALS progression in mice. Neuroscience, 240, 129&#x2013;134. 10.1016/j.neuroscience.2013.02.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2013.02.035</ArticleId><ArticleId IdType="pmc">PMC3665351</ArticleId><ArticleId IdType="pubmed">23458708</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe, P. A. , &amp; Henderson, R. D. (2010). Effects of gender in amyotrophic lateral sclerosis. Gender Medicine, 7(6), 557&#x2013;570. 10.1016/j.genm.2010.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarthing, K. , Prakash, N. , &amp; Simuni, T. (2019). Clinical trial s &#x2013; dyskinesia. Journal of Parkinson's Disease, 9(3), 449&#x2013;465. 10.3233/JPD-199002</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-199002</ArticleId><ArticleId IdType="pmc">PMC6704371</ArticleId><ArticleId IdType="pubmed">31356217</ArticleId></ArticleIdList></Reference><Reference><Citation>Mediavilla, T. , Est&#xe9;vez&#x2010;Silva, H. M. , Kumar, V. , Parween, S. , Giacobbo, B. L. , Or&#xe4;dd, G. , Marcellino, D. , &amp; Sultan, F. (2020). In vivo detection of cortical white matter changes associated with early and late motor deficits in a SOD1 G93A ALS mouse model, in FENS 2020 virtual forum. Glasgow, Scotland.</Citation></Reference><Reference><Citation>Miana&#x2010;Mena, F. J. , Mu&#xf1;oz, M. J. , Yag&#xfc;e, G. , Mendez, M. , Moreno, M. , Ciriza, J. , Zaragoza, P. , &amp; Osta, R. (2005). Optimal methods to characterize the G93A mouse model of ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 6(1), 55&#x2013;62. 10.1080/14660820510026162</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820510026162</ArticleId><ArticleId IdType="pubmed">16036427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder, D. W. , Kurland, L. T. , Offord, K. P. , &amp; Beard, C. M. (1986). Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology, 36(4), 511&#x2013;517. 10.1212/WNL.36.4.511</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.36.4.511</ArticleId><ArticleId IdType="pubmed">3960325</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura, T. , Ishima, T. , Iyo, M. , &amp; Hashimoto, K. (2008). Potentiation of nerve growth factor&#x2010;induced neurite outgrowth by fluvoxamine: role of sigma&#x2010;1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE, 3(7), e2558. 10.1371/journal.pone.0002558</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002558</ArticleId><ArticleId IdType="pmc">PMC2435603</ArticleId><ArticleId IdType="pubmed">18596927</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliv&#xe1;n, S. , Calvo, A. C. , Rando, A. , Mu&#xf1;oz, M. J. , Zaragoza, P. , &amp; Osta, R. (2015). Comparative study of behavioural tests in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Experimental Animals, 64(2), 147&#x2013;153. 10.1538/expanim.14-0077</Citation><ArticleIdList><ArticleId IdType="doi">10.1538/expanim.14-0077</ArticleId><ArticleId IdType="pmc">PMC4427729</ArticleId><ArticleId IdType="pubmed">25736480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono, Y. , Tanaka, H. , Takata, M. , Nagahara, Y. , Noda, Y. , Tsuruma, K. , Shimazawa, M. , Hozumi, I. , &amp; Hara, H. (2014). SA4503, a sigma&#x2010;1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models. Neuroscience Letters, 559, 174&#x2013;178. 10.1016/j.neulet.2013.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.12.005</ArticleId><ArticleId IdType="pubmed">24334165</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni, S. , &amp; Wills, A.&#x2010;M. (2013). High&#x2010;fat and ketogenic diets in amyotrophic lateral sclerosis. Journal of Child Neurology, 28(8), 989&#x2013;992. 10.1177/0883073813488669</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073813488669</ArticleId><ArticleId IdType="pmc">PMC4438106</ArticleId><ArticleId IdType="pubmed">23666040</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli, P. , &amp; Brown, R. H. (2006). Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nature Reviews. Neuroscience, 7(9), 710&#x2013;723. 10.1038/nrn1971</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1971</ArticleId><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Penke, B. , Fulop, L. , Szucs, M. , &amp; Frecska, E. (2018). The role of Sigma&#x2010;1 receptor, an intracellular chaperone in neurodegenerative diseases. Current Neuropharmacology, 16(1), 97&#x2013;116. 10.2174/1570159X15666170529104323</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X15666170529104323</ArticleId><ArticleId IdType="pmc">PMC5771390</ArticleId><ArticleId IdType="pubmed">28554311</ArticleId></ArticleIdList></Reference><Reference><Citation>Percie du Sert, N. , Hurst, V. , Ahluwalia, A. , Alam, S. , Avey, M. T. , Baker, M. , Browne, W. J. , Clark, A. , Cuthill, I. C. , Dirnagl, U. , Emerson, M. , Garner, P. , Holgate, S. T. , Howells, D. W. , Karp, N. A. , Lazic, S. E. , Lidster, K. , MacCallum, C. J. , Macleod, M. , &#x2026; W&#xfc;rbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. 10.1371/journal.pbio.3000410</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000410</ArticleId><ArticleId IdType="pmc">PMC7360023</ArticleId><ArticleId IdType="pubmed">32663219</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov, D. , Mansfield, C. , Moussy, A. , &amp; Hermine, O. (2017). ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Frontiers in Aging Neuroscience, 9, 68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan, N. K. , Visser, A. K. D. , Schepers, M. , Luurtsema, G. , Nyakas, C. J. , Elsinga, P. H. , Ishiwata, K. , Dierckx, R. A. J. O. , &amp; Van Waarde, A. (2014). Dose&#x2010;dependent sigma&#x2010;1 receptor occupancy by donepezil in rat brain can be assessed with (11)C&#x2010;SA4503 and microPET. Psychopharmacology, 231(20), 3997&#x2013;4006. 10.1007/s00213-014-3533-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-014-3533-2</ArticleId><ArticleId IdType="pubmed">24639047</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton, A. E. , Chio, A. , &amp; Traynor, B. J. (2014). State of play in amyotrophic lateral sclerosis genetics. Nature Neuroscience, 17(1), 17&#x2013;23. 10.1038/nn.3584</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht, W. , &amp; Philips, T. (2013). The changing scene of amyotrophic lateral sclerosis. Nature Reviews. Neuroscience, 14(4), 248&#x2013;264. 10.1038/nrn3430</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen, D. R. , Siddique, T. , Patterson, D. , Figlewicz, D. A. , Sapp, P. , Hentati, A. , Donaldson, D. , Goto, J. , O'Regan, J. P. , Deng, H. X. , Rahmani, Z. , Krizus, A. , McKenna&#x2010;Yasek, D. , Cayabyab, A. , Gaston, S. M. , Berger, R. , Tanzi, R. E. , Halperin, J. J. , Herzfeldt, B. , &#x2026; Brown, R. H. Jr. (1993). Mutations in cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362(6415), 59&#x2013;62. 10.1038/362059a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotunno, M. S. , Auclair, J. R. , Maniatis, S. , Shaffer, S. A. , Agar, J. , &amp; Bosco, D. A. (2014). Identification of a misfolded region in superoxide dismutase 1 that is exposed in amyotrophic lateral sclerosis. The Journal of Biological Chemistry, 289(41), 28527&#x2013;28538. 10.1074/jbc.M114.581801</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.581801</ArticleId><ArticleId IdType="pmc">PMC4192504</ArticleId><ArticleId IdType="pubmed">25164820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryskamp, D. A. , Korban, S. , Zhemkov, V. , Kraskovskaya, N. , &amp; Bezprozvanny, I. (2019). Neuronal Sigma&#x2010;1 receptors: signaling functions and protective roles in neurodegenerative diseases. Frontiers in Neuroscience, 13, 862. 10.3389/fnins.2019.00862</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00862</ArticleId><ArticleId IdType="pmc">PMC6736580</ArticleId><ArticleId IdType="pubmed">31551669</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahlholm, K. , &#xc5;rhem, P. , Fuxe, K. , &amp; Marcellino, D. (2013). The dopamine stabilizers ACR16 and (&#x2212;)&#x2010;OSU6162 display nanomolar affinities at the sigma&#x2010;1 receptor. Molecular Psychiatry, 18(1), 12&#x2013;14. 10.1038/mp.2012.3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.3</ArticleId><ArticleId IdType="pubmed">22349783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahlholm, K. , Sijbesma, J. W. A. , Maas, B. , Kwizera, C. , Marcellino, D. , Ramakrishnan, N. K. , Dierckx, R. A. J. O. , Elsinga, P. H. , &amp; Van Waarde, A. (2015). Pridopidine selectively occupies sigma&#x2010;1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology, 232(18), 3443&#x2013;3453. 10.1007/s00213-015-3997-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-015-3997-8</ArticleId><ArticleId IdType="pmc">PMC4537502</ArticleId><ArticleId IdType="pubmed">26159455</ArticleId></ArticleIdList></Reference><Reference><Citation>

Sean, M.
 (2019). Healey &amp; AMG center for ALS at mass general launches first ALS platform trial with 5 promising drugs. Available from: https://www.massgeneral.org/neurology/als/news/healey-center-launches-first-als-platform-trial-with-5-promising-drugs
</Citation></Reference><Reference><Citation>Slowie, L. A. , Paige, M. S. , &amp; Antel, J. P. (1983). Nutritional considerations in the management of patients with amyotrophic lateral sclerosis (ALS). Journal of the American Dietetic Association, 83(1), 44&#x2013;47. 10.1016/S0002-8223(21)07760-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-8223(21)07760-9</ArticleId><ArticleId IdType="pubmed">6863783</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau, T. M. , Grambsch, P. M. , &amp; Pankratz, V. S. (2003). Penalized survival models and frailty. Journal of Computational and Graphical Statistics, 12(1), 156&#x2013;175. 10.1198/1061860031365</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/1061860031365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella, S. , Santamato, A. , &amp; Lamberti, P. (2009). Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatric Disease and Treatment, 5, 577&#x2013;595. 10.2147/NDT.S7788</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S7788</ArticleId><ArticleId IdType="pmc">PMC2785861</ArticleId><ArticleId IdType="pubmed">19966906</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>